-+ 0.00%
-+ 0.00%
-+ 0.00%

Fangsheng Pharmaceutical (603998.SH): Shuangzao Anshen granules approved for drug clinical trials

Zhitongcaijing·11/02/2026 11:25:06
Listen to the news

Zhitong Finance App News, Fangsheng Pharmaceutical (603998.SH) issued an announcement. On October 30, 2026, the company's innovative traditional Chinese medicine research and development project Shuangzao Anshen Granules received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. Shuangzao Anshen granules are clinically effective empirical formulations developed based on years of clinical diagnosis and treatment practices to treat insomnia (hepatic and renal deficiency). The whole formula focuses on nourishing the liver and kidney, nourishing blood and calming the mind. It is used to treat insomnia (hepatic and renal deficiency), insomnia, easy awakening, palpitations, pain in the lower back and knee, dizziness, tinnitus, and forgetting.